The ambition is to enable patients with IMD to have a normal life expectancy, without disability, and to reduce the consequences of these diseases and their complications, based on innovative research programmes: This approach will lead to innovative biomarkers for diagnosis and prognosis, as well as to new therapeutic targets capable of offering real precision medicine and prevention. All these data will be integrated into health data warehouses. These diseases are characterised by the key role of the interaction between dysmetabolism and inflammation (called meta-inflammation) in their physiopathology, their severity, their complications, their comorbidity and their resistance to disease, co-morbidities and resistance to treatment.īased on a holistic approach, PRIME will include patients, with a target of 2,000 inclusions per year, in a unique database and bio-bank, to feed basic and translational research. Their incidence has been steadily increasing over the past 30 years and the Hauts-de-France region has the highest prevalence in France.
These diseases include mutually aggravating conditions: obesityĭiabetes, NASH and inflammatory digestive, skin and autoimmune diseases. PRIME is a multidisciplinary project on prevention, care and research into inflammatory metabolic diseases (IMD).
0 kommentar(er)
